Valo Health

Valo Health leverages its AI-driven drug discovery platform Opal that is aimed at predicting molecules that can be used as drugs against new diseases. The platform uses a dataset of more than 125-million-patient-years (as of January 2021) combined from thousands of sources. It integrates machine learning, cloud computing, and data to create an entirely new drug discovery and development process.  As of June 2021, Valo reported that Opal had built more than 30,000 predictive models and two billion predictions. 

As of June 2023, the company has 17 programs in its pipeline in a variety of areas including cardiovascular, cancer, and degenerative disorders. Two of the company’s drug candidates are about to launch Phase 2 clinical trials (one by the end of 2021 and the other in the first half of 2022). 

Valo Health acquired Courier Therapeutics in July 2021 and expanded its focus from small molecules to biologics. It also acquired TARA Biosystem s in April 2022 to develop an AI platform focused on cardiovascular diseases.

Key customers and partnerships

The company entered a multi-year strategic partnership with Charles River Laboratories in April 2022 to launch Logica, an integrated AI-powered drug discovery solution. In September 2023,  the company entered a partnership with pharmaceutical manufacturing company Novo Nordisk to discover and develop new treatments for cardiometabolic diseases.

Funding and financials

The company raised USD 110 million in an extended Series B financing round in March 2021, bringing its total Series B funding to USD 300 million. It also announced a SPAC deal with Khosla Ventures in June 2021, which was later called off in November 2021 citing unfavourable market conditions.